Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Ossenkoppele, G J; Breems, D A; Stuessi, G; van Norden, Y; Bargetzi, M; Biemond, B J; A von dem Borne, P; Chalandon, Y; Cloos, J; Deeren, D; Fehr, M; Gjertsen, B; Graux, C; Huls, G; Janssen, J J J W; Jaspers, A; Jongen-Lavrencic, M; de Jongh, E; Klein, S K; van der Klift, M; van Marwijk Kooy, M; Maertens, J; Michaux, L; van der Poel, M W M; van Rhenen, A; Tick, L; Valk, P; Vekemans, M C; van der Velden, W J F M; de Weerdt, O; et al (2020). Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS. Leukemia, 34(10):2820.
Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Additional indexing
| Item Type: | Journal Article, refereed, original work |
|---|---|
| Communities & Collections: | 04 Faculty of Medicine > University Hospital Zurich > Clinic for Oncology and Hematology |
| Dewey Decimal Classification: | 610 Medicine & health |
| Scopus Subject Areas: | Health Sciences > Hematology
Health Sciences > Oncology Life Sciences > Cancer Research |
| Language: | English |
| Date: | October 2020 |
| Deposited On: | 19 Oct 2020 16:59 |
| Last Modified: | 27 Jan 2022 02:47 |
| Publisher: | Nature Publishing Group |
| ISSN: | 0887-6924 |
| OA Status: | Closed |
| Free access at: | Publisher DOI. An embargo period may apply. |
| Publisher DOI: | https://doi.org/10.1038/s41375-020-0994-7 |
| PubMed ID: | 32733013 |
Download
Full text not available from this repository.
View at publisher
Get full-text in a library
Ossenkoppele, G J